Therapeutic Efficacy of Combination Therapy Using Oral Cyclosporine with a Dietary Supplement (Pantogar®) in Twenty-Nail Dystrophy

Su Jin Oh, Jeong Eun Kim, Joo Yeon Ko, Young Suck Ro

Department of Dermatology, Hanyang University Seoul Hospital, Seoul, Korea

Background: Twenty-nail dystrophy (TND) is an acquired idiopathic disease characterized by dull, thin, lusterless, and fragile nails with fissuring, small regular pits, and excessive longitudinal ridging. Although various treatment modalities have been performed in order to treat TND, the effects of these treatments are controversial. Objective: To evaluate the effectiveness of oral cyclosporine in TND. Methods: A total of 38 patients with TND were treated with combination therapy using oral cyclosporine with a pantothenic acid complex-based dietary supplement (Pantogar®; Merz Pharmaceuticals GmbH, Germany), whereas 44 patients were treated with the pantothenic acid complex-based dietary supplement alone. The therapeutic efficacy in each group was retrospectively evaluated using medical records and clinical photographs. Results: The cyclosporine therapy group had significantly more patients whose improvement was rated as almost clear, marked, or moderate compared to the control group (p<0.001). While the mean CHATS (Color, Hyperkeratosis, Area, Thickness, Separation) score of the cyclosporine therapy group was decreased by 13.45 (from 30.95 to 17.5) after treatment, the mean CHATS score of the control group was only decreased by 8 (from 29.43 to 21.43, p<0.001). Moreover, greater Dermatology Life Quality Index changes after treatment were observed in the cyclosporine therapy group (p=0.085). Conclusion: Oral cyclosporine can be a valuable therapeutic option in patients with TND. (Ann Dermatol 29(5) 608∼613, 2017)

Keywords: Cyclosporine, Pantothenic acid, Twenty-nail dystrophy

INTRODUCTION

Twenty-nail dystrophy (TND) of childhood was first used by Hazelrigg et al.1 to describe an idiopathic nail dystrophy in six children, which began insidiously in early childhood, and was characterized by longitudinal ridging and roughness. TND as also been referred to as ‘trachyonychia’, a term that is well suited to the clinical appearance of the affected nails2-4. The quality of life of patients with TND is generally decreased due to the resulting deformation of nails. The exact etiology of TND remains unclear.

Many treatment modalities are used in order to prevent nail destruction and reduce resolving duration. Therapeutic modalities such as topically-applied psoralen-ultra violet A (PUVA), triamcinolone acetonide injections, topical steroid, and systemic agents include prednisolone, anti-malarials, and etretinate in TND have been tried5-13. However, these treatments have low efficacies. In addition, injections are painful and thus are difficult to administer to children. Thus, a standard treatment for TND has not yet been established.

Cyclosporine is a common therapeutic agent that selectively inhibits T-cell activation, has been successfully used for various skin diseases and continues to play an im-
Oral Cyclosporine in Twenty-Nail Dystrophy

Table 1. Inclusion and exclusion criteria

| Inclusion criteria                                      | Exclusion criteria                                                                 |
|--------------------------------------------------------|-------------------------------------------------------------------------------------|
| Patient with twenty-nail dystrophy                      | Patient with infectious diseases such as onychomycosis and paronychia proved by KOH |
| Patient who is physically healthy without any associated disease | Patient with any skin or mucosal lesions                                           |
|                                                        | Patient with uncontrolled hypertension, renal disease, serious infections, and a previous history of malignancy |
|                                                        | Patient who are judged to be not suitable for the study                             |

Methods

1) Patient characteristics

We examined demographic information such as sex, age, body weight, disease duration, fingernail or toenail involvement, treatment history (e.g., intralesional steroid injections, topical steroids, nail operations), treatment duration, and follow-up period.

2) Cyclosporine and pantothenic acid complex-based dietary supplement (Pantogar®) regimen and follow-up

Due to ethical reasons, all 82 patients with TND were treated with a pantothenic acid complex-based dietary supplement (Pantogar®, 2~4 capsule/day) that helps nail growth. Of these 82 patients, 38 patients were also treated with cyclosporine. Patients who did not receive oral cyclosporine were assigned to the control group. During the treatment period, other treatments such as local steroid injection, PUVA, and systemic steroids were not administered concurrently. All patients visited the Department of Dermatology regularly (once every 2 to 4 weeks). The cyclosporine dosage (100 mg, 25 mg/capsule, Cipol-N®; Chongkundang, Seoul, Korea) was adjusted to 3~5 mg/kg per day at each visit according to the patient’s treatment response. Blood pressure was checked at every visit. Laboratory examination, including complete blood cell count, liver function test, kidney function test, and lipid profile, were performed before initiation of cyclosporine treatment and every 12 to 16 weeks thereafter.

3) Clinical photographs

The extent of clinical improvement was evaluated using clinical photographs that focused on the fingernail or toenail plates. Ten fingernail or toenail plates were assessed when either fingernails or toenails were involved. All twenty nails were evaluated when both fingernails and toenails were involved. Clinical photographs of the nail plate surface were captured with a digital camera (Canon DS 126201; Canon, Tokyo, Japan) at each visit. Clinical photographs were evaluated by two dermatologists. Dermatologists blindly evaluated patients’ photographs without looking at patients’ information. Nail plate surfaces were classified as almost clear (>75% improvement of nail dystrophy), marked improvement (>50% improvement), moderate improvement (>25% improvement), slight improvement (0%~25% improvement), no change or worse.

The Cleveland Foot and Ankle Clinic developed a clinical onychomycosis nail severity scoring system called the CHATS system, which is a system for scoring the severity.
of onychomycosis in the fingernail and toenail\textsuperscript{18}. Since a standard TND severity scoring system has not yet been established, we used the CHATS system. The CHATS score (C, abnormal coloration; H, hyperkeratosis beneath the nail; A, area of involvement; T, thickening; and S, subungual separation or onycholysis) of each patient was evaluated using the clinical photographs\textsuperscript{9}. One point is assigned for each of the above criteria, except for the area of involvement, which can be assigned up to six points if the entire nail plate is involved (Fig. 1).

4) Dermatology Life Quality Index

The Dermatology Life Quality Index (DLQI) score of each patient was evaluated. At the time of visiting to the hospital, patient’s quality of life was recorded in the medical charts. A few questions that were not recorded in the charts were collected through telephone interview. The DLQI questionnaire includes a total of 10 questions related to symptoms, feelings, daily activities, leisure activities, work/school, personal relationships and treatment\textsuperscript{19}. Each question was answered on a 4-point Likert scale (not at all, 0 points; a little, 1 point; a lot, 2 points; and very much, 3 points). The questionnaire yielded a possible maximum score of 30 points. A higher score indicates greater impairment of life quality.

5) Statistical analysis

Data were analyzed with IBM SPSS Statistics ver. 22.0 for Windows (IBM Co., Armonk, NY, USA). Differences in demographic data between the two groups were analyzed using the t-test, the Mann-Whitney U-test, and the chi-square test. The examined covariates included age, sex, body weight, disease duration, site of involvement, treatment history, treatment duration, and follow-up period. Two-way ANOVA using site of involvement as covariate was performed to analyze the significance of differences in treatment efficacy, changes in DLQI score, and changes in CHATS scores between the two groups. \( p \)-values \(< 0.05\) were defined as statistically significant.

RESULTS

Demographic analysis

The patient demographic and descriptive variables are shown in Table 2. A total of 82 patients who were diagnosed with TND were included in this study. The cyclosporine therapy group consisted of 16 males and 22 females with a mean age of 41.55 \( \pm \) 18.66 years. The control group consisted of 18 males and 26 females with a mean age of 43.41 \( \pm \) 20.15 years. Body weight, disease duration, treatment history, treatment duration, and follow-up period were not significantly different between two treatment groups. Fingernail involvement was observed more often in cyclosporine therapy group than the control group; this difference was statistically significant (\( p=0.006\), Table 2).
Treatment efficacy

Patients who were treated with combination therapy using oral cyclosporine with the pantothenic acid complex-based dietary supplement showed better outcomes than those who were treated with the pantothenic acid complex-based dietary supplement alone (Fig. 2). The extent of clinical improvement was evaluated using clinical photographs. Of the 38 patients in the cyclosporine therapy group, nail plate roughness had almost cleared up in 5 patients (13.2%), 8 patients (21.1%) presented with marked improvement, 18 patients (47.4%) showed moderate improvement, and 7 patients (18.4%) showed slight improvement after treatment. No patients in the control group were almost clear of nail plate roughness. Five of the 44 patients in the control group (11.4%) showed marked improvement, 13 patients (29.5%) showed moderate improvement, and 26 patients (59.1%) showed slight improvement. No patient in either of the groups was scored as “no change” or “worse”. The cyclosporine therapy group had more patients whose nail roughness was almost clear, or whose improvement was marked or moderate than the control group. There was a statistically significant difference between the two groups (p=0.001, Table 3).

While the mean CHATS score in the cyclosporine therapy group was decreased by 13.45 (from 30.95 to 17.45), the mean score in the control group was decreased by 8 (from 29.43 to 21.43); this difference was statistically significant (F[1,76]=21.392, p<0.001; Table 4).

Changes of DLQI according to the treatment

The mean pretreatment DLQI score in the cyclosporine therapy group was 16.16. After treatment, the mean DLQI score was significantly decreased to 7.9. The mean DLQI score in the control group was decreased from 15.5 to 10.2 after treatment. The pretreatment to post-treatment

---

**Table 3.** Comparison of therapeutic efficacies in the combination therapy group versus the control group

| Classification       | Cyclosporine therapy group (n=38) | Control group (n=44) | p-value |
|----------------------|-----------------------------------|----------------------|---------|
| Almost clear         | 5 (13.2)                          | 0 (0)                |         |
| Marked improvement   | 8 (21.1)                          | 5 (11.4)             |         |
| Moderate improvement | 18 (47.4)                         | 13 (29.5)            | 0.001*  |
| Slight improvement   | 7 (18.4)                          | 26 (59.1)            |         |
| No change or worse   | 0 (0)                             | 0 (0)                |         |

Values are presented as number (%). *p<0.05.

**Table 4.** Changes in pre-treatment to post-treatment CHATS and DLQI scores

|                      | Cyclosporine therapy group | Control group | p-value |
|----------------------|---------------------------|---------------|---------|
| CHATS score change   | $-13.45\pm191.50$         | $-8\pm101.16$ | <0.001* |
| DLQI score change    | $-8.26\pm3.20$            | $-5.3\pm3.89$ | 0.085   |

Values are presented as mean± standard deviation. CHATS: C (abnormal coloration), H (hyperkeratosis beneath the nail), A (area of involvement), T (thickening), and S (subungual separation or onycholysis), DLQI: Dermatology Life Quality Index. *p<0.05.
change in DLQI score was greater in the cyclosporine therapy group than the control group; this difference was statistically significant (F[1,76] = 3.047, p = 0.085; Table 4).

Adverse effects of cyclosporine

Adverse effects of cyclosporine were reported in 4 of the 38 patients (10.53%) and consisted of gastrointestinal symptoms such as nausea and abdominal discomfort. All reported adverse effects were mild. Other severe adverse reactions and laboratory abnormalities were not observed in this study.

DISCUSSION

TND is usually idiopathic, i.e., it may occur without any associated dermatological disease. TND may be associated with various dermatological conditions including lichen planus, psoriasis, and alopecia areata, rare associations with vitiligo and incontinentia pigmenti have also been reported. In our study, we focused on idiopathic TND that is not associated with any other dermatological condition. Inflammation of the nail matrix may produce TND. Most patients with TND show spongiotic dermatitis, with mild inflammation associated with lymphocytic exocytosis of the proximal nail fold and proximal nail matrix. Cyclosporine has a selective effect on T-cell proliferation by inhibiting the synthesis of interleukin-2. Cyclosporine acts primarily as a systemic immune modulator by binding cyclophilin and blocking calcineurin. Cyclosporine is currently used by dermatologists in the management of psoriasis and atopic dermatitis. The therapeutic efficacy of cyclosporine in TND has been reported previously.

Lee et al. reported that low dose cyclosporine administration (2.0–3.5 mg/kg per day) may be beneficial in the management of TND and in improving quality of life. In the above study, the clinical improvement was evaluated by using the clinical photos. The evaluation was classified as complete resolution, significant improvement (>50% improvement of fingernail dystrophy), slight improvement (<50% improvement), or no change. All patients with TND (n = 15) presented with slight improvement of fingernail plate roughness after one month. After 6 months of treatment, 13 patients (86.7%) showed significant improvement of TND and two patients maintained slight improvement (13.3%). The mean pretreatment DLQI score was 18.1. After treatment, the mean DLQI score was significantly decreased to 9.5. However, the above study has small sample size and no comparable control group was included. Furthermore, the above study only evaluated clinical improvement of fingernails, and excluded toenails. In the present study, to evaluate the effectiveness of cyclosporine in patients with TND, a total of 38 patients with TND were treated with combination therapy using oral cyclosporine with Pantogar® and 44 patients were treated with Pantogar®. The therapeutic efficacy in each group was retrospectively evaluated using medical records and clinical photographs. The pretreatment to post-treatment DLQI change was greater in the cyclosporine therapy group (p = 0.085). This result demonstrates that cyclosporine administration may be beneficial in improving the quality of life in patients with TND. The cyclosporine therapy group had more patients who were almost clear of nail roughness or whose improvement was rate as marked or moderate compared to the control group (p = 0.001). The mean CHATS score in the cyclosporine therapy group decreased by 13.45 after treatment, but decreased by only 8 in control group. This difference was statistically significant (p < 0.001). No severe adverse reactions to cyclosporine were observed in this study. Most of patients were satisfied about the clinical improvement after 6 months of treatment. Referencing the above out result, authors recommend that administer 3~5 mg/kg cyclosporine per day in TND for about 6 months or longer.

We hypothesize that the therapeutic effectiveness of cyclosporine in TND results from its dramatic effects on T-cell function, as well as on pro-inflammatory cytokine release. In this manner, cyclosporine might suppress the spongiotic dermatitis and lymphocytic infiltration of the nail matrix observed in patients with TND.

The adverse effects of cyclosporine are, for the most part, dose-dependent and related to therapy duration. Gastrointestinal discomfort is a common side effect of cyclosporine administration. Cyclosporine is contraindicated in patients with uncontrolled hypertension, renal disease, serious infections, and a previous history of malignancy, excluding basal cell carcinoma. In our study, we excluded patients with any of the above diseases. Moreover, laboratory abnormalities or severe adverse reactions were not observed during the cyclosporine treatment period. Four of the 38 patients (10.53%) reported nausea and abdominal discomfort; however, these symptoms were mild and were alleviated by taking digestive medication. Using the recommended monitoring protocols has been shown to result in a significant decrease in the incidence of cyclosporine-related toxicities.

Although this is the first report to assess the treatment efficacy of cyclosporine in patients with TND and to use a control group, there are some limitations to our study. First, the TND nail severity score may be less accurate due to use of a nail severity scoring system for onychomycosis. Second, our results may be subject to recall bias, since the pretreatment DLQI score was estimated retrospectively ac-
Oral Cyclosporine in Twenty-Nail Dystrophy

ter treatment. Third, the studied population was from a small geographic area and thus our results may not be generalizable to a larger population. Fourth, our study was performed at a single-center, meaning that it may subject to selection bias. It was also a retrospective study and there may have been multiple confounding factors for which could not control. Future large, randomized, controlled multicenter trials are required to validate the correlations we report here.

In conclusion, our results show that cyclosporine is an effective treatment option for TND. Since few studies have assessed TND treatments, our study is of note in that it was conducted using a relatively large number of patients with TND. Furthermore, our study is a milestone because few studies have reported the effects of cyclosporine in TND.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Hazelrigg DE, Duncan WC, Jarratt M. Twenty-nail dystrophy of childhood. Arch Dermatol 1977;113:73-75.
2. Tosti A, Bardazzi F, Piraccini BM, Fanti PA. Idiopathic trachyonychia (twenty-nail dystrophy): a pathological study of 23 patients. Br J Dermatol 1994;131:866-872.
3. Scheinfeld NS. Trachyonychia: a case report and review of manifestations, associations, and treatments. Cutis 2003;71:299-302.
4. Samman PD. Trachyonychia (rough nails). Br J Dermatol 1979;101:701-705.
5. Halkier-Sørensen L, Cramers M, Kragballe K. Twenty-nail dystrophy treated with topical PUVA. Acta Derm Venereol 1990;70:510-511.
6. Abell E, Samman PD. Intradermal triamcinolone treatment of nail dystrophies. Br J Dermatol 1973;89:191-197.
7. Khoo BP, Giam YC. A pilot study on the role of intralesional triamcinolone acetonide in the treatment of pitted nails in children. Singapore Med J 2000;41:66-68.
8. Park JM, Cho HH, Kim WJ, Mun JH, Song M, Kim HS, et al. Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of trachyonychia: an open-label study. Ann Dermatol 2015;27:371-375.
9. Evans AV, Roest MA, Fletcher CL, Lister R, Hay RJ. Isolated lichen planus of the toe nails treated with oral prednisolone. Clin Exp Dermatol 2001;26:412-414.
10. Mostafa WZ. Lichen planus of the nail: treatment with antimalarials. J Am Acad Dermatol 1989;20:289-290.
11. Kato N, Ueno H. Isolated lichen planus of the nails treated with etretinate. J Dermatol 1993;20:577-580.
12. Favber EM, Nall L. Nail psoriasis. Cutis 1992;50:174-178.
13. Arnold WP, Gerritsen MJ, van de Kerkhof PC. Response of nail psoriasis to cyclosporin. Br J Dermatol 1993;129:750-751.
14. Biren CA, Barr RJ. Dermatologic applications of cyclosporine. Arch Dermatol 1986;122:1028-1032.
15. Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 2010;63:925-946.
16. Lee YB, Cheon MS, Eun YS, Cho BK, Park YG, Park HJ. Cyclosporin administration improves clinical manifestations and quality of life in patients with 20-nail dystrophy: case series and survey study. J Dermatol 2012;39:1064-1065.
17. Lengg N, Heidecker B, Seifert B, Trüeb RM. Dietary supplement increases anagen hair rate in women with telogen effluvium: results of a double-blind, placebo-controlled trial. Therapy 2007;4:59-65.
18. Bodman MA. Nail dystrophies. Clin Podiatr Med Surg 2004;21:663-687, viii.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
20. Alkiewicz J. Trachyonychia. Ann Dermatol Syphiligr 1950;10:136-140.
21. Tosti A, Piraccini BM, Iorizzo M. Trachyonychia and related disorders: evaluation and treatment plans. Dermatol Ther 2002;15:121-125.
22. Peloro TM, Pride HB. Twenty-nail dystrophy and vitiligo: a rare association. J Am Acad Dermatol 1999;40:488-490.
23. Scardamaglia L, Howard A, Sinclair R. Twenty-nail dystrophy in a girl with incontinentia pigmenti. Australas J Dermatol 2003;44:71-73.
24. Cavani A, De Luca A. Allergic contact dermatitis: novel mechanisms and therapeutic perspectives. Curr Drug Metab 2010;11:228-233.
25. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010;63:949-972.